Anti-programmed cell death protein-1/ligand-1 therapy in different cancers

Immunologic checkpoint blockade with antibodies against the programmed cell death protein-1 (PD-1) or its ligand (PD-L1) is an effective method for reversing cancer immunosuppression and thereby promoting immune responses against several cancer types. Anti-PD-1 and anti-PD-L1 antibodies have resulte...

Descripción completa

Detalles Bibliográficos
Autores principales: Homet Moreno, B, Ribas, A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Minireview
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453674/
https://www.ncbi.nlm.nih.gov/pubmed/25856776
http://dx.doi.org/10.1038/bjc.2015.124

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453674/
https://www.ncbi.nlm.nih.gov/pubmed/25856776
http://dx.doi.org/10.1038/bjc.2015.124

Ejemplares similares